Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer

NCT01506609 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT01506609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01506609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer
Lead sponsor
AbbVie
Phase
Phase 2
Overall status
Completed
Start date
January 23, 2012
Completion date
September 2, 2020
Enrollment
294 (actual)
Sites
120

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic breast cancer